Idera Pharmaceuticals, Inc. (IDRA)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Idera Pharmaceuticals, Inc. (IDRA) with AI Score 44/100 (Weak). Idera Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs for rare disease indications. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Idera Pharmaceuticals, Inc. (IDRA) Healthcare & Pipeline Overview
Idera Pharmaceuticals, Inc. specializes in developing drugs for rare diseases, with a focus on immuno-oncology. Their lead candidate, Tilsotolimod, targets TLR9 to stimulate the immune system against solid tumors. The company operates within the competitive biotechnology sector, collaborating with major players like Bristol-Meyers Squibb.
Investment Thesis
Idera Pharmaceuticals presents a high-risk, high-reward investment profile characteristic of early-stage biotechnology companies. The primary value driver is the clinical development and potential commercialization of Tilsotolimod. Successful clinical trial outcomes, particularly in squamous cell carcinoma of the head and neck and colorectal cancer, could significantly increase the company's valuation. The collaboration with Bristol-Meyers Squibb provides validation and potential future revenue streams. However, the company's negative P/E ratio of -0.06 reflects its current lack of profitability and reliance on future product success. Investors should closely monitor clinical trial data, regulatory milestones, and partnership developments to assess the viability of Idera's pipeline and its long-term growth potential. The company's small size (13 employees) also introduces operational risks.
Based on FMP financials and quantitative analysis
Key Highlights
- Tilsotolimod (IMO-2125) is the lead product candidate, targeting TLR9 for immune stimulation in cancer treatment.
- Collaboration agreement with Bristol-Meyers Squibb validates the potential of Idera's technology.
- Focus on rare disease indications offers potential for niche market dominance and premium pricing.
- Negative P/E ratio of -0.06 indicates the company is currently not profitable and relies on future product success.
- Small employee base of 13 introduces operational risks and dependence on key personnel.
Competitors & Peers
Strengths
- Proprietary TLR9 agonist technology with potential in immuno-oncology.
- Collaboration with Bristol-Meyers Squibb provides validation and resources.
- Focus on rare diseases allows for potential orphan drug designation and accelerated approval pathways.
- Experienced management team with expertise in drug development.
Weaknesses
- Limited financial resources and reliance on future funding.
- High dependence on the success of Tilsotolimod.
- Small employee base introduces operational risks.
- Negative P/E ratio indicates current lack of profitability.
Catalysts
- Clinical trial data releases for Tilsotolimod in squamous cell carcinoma of the head and neck.
- Potential regulatory submissions for Tilsotolimod based on clinical trial results.
- Continued enrollment and progress in ongoing clinical trials.
- Exploration of new indications for Tilsotolimod.
- Partnership and collaboration opportunities with other pharmaceutical companies.
Risks
- Clinical trial failures or negative data readouts for Tilsotolimod.
- Regulatory delays or rejection of Tilsotolimod.
- Competition from other immuno-oncology therapies.
- Dependence on future funding and capital raising.
- Patent expiration and generic competition.
Growth Opportunities
- Expansion of Tilsotolimod into New Cancer Indications: Idera has the opportunity to expand the use of Tilsotolimod into additional cancer types beyond squamous cell carcinoma of the head and neck and colorectal cancer. Exploring its efficacy in other solid tumors or hematological malignancies could significantly broaden its market potential. The market for cancer therapies is substantial, with global oncology drug sales projected to reach hundreds of billions of dollars annually. Success in new indications could drive significant revenue growth for Idera.
- Advancement of Pipeline Programs: Idera can focus on advancing other preclinical or early-stage pipeline programs. Developing new drug candidates targeting different aspects of the immune system or other disease pathways could diversify the company's product portfolio and reduce its reliance on Tilsotolimod. This requires significant investment in research and development, but could lead to long-term growth and value creation.
- Strategic Partnerships and Collaborations: Idera can pursue additional strategic partnerships and collaborations with larger pharmaceutical companies or other biotechnology firms. These partnerships can provide access to funding, expertise, and commercialization capabilities, accelerating the development and launch of Idera's products. The collaboration with Bristol-Meyers Squibb serves as a model for future partnerships.
- Orphan Drug Designation and Accelerated Approval Pathways: Idera's focus on rare diseases allows it to leverage orphan drug designation and accelerated approval pathways offered by regulatory agencies. These programs provide incentives such as market exclusivity and expedited review processes, which can significantly reduce the time and cost of bringing new drugs to market. This is a key advantage for companies targeting niche indications.
- Personalized Medicine Approaches: Idera can explore personalized medicine approaches to identify patients who are most likely to respond to Tilsotolimod or other therapies. By developing companion diagnostics or biomarkers, the company can tailor treatment to individual patients, improving efficacy and reducing the risk of adverse events. This requires investment in genomic and proteomic research, but could lead to more effective and targeted therapies.
Opportunities
- Expansion of Tilsotolimod into new cancer indications.
- Advancement of other pipeline programs.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Leveraging personalized medicine approaches to improve treatment efficacy.
Threats
- Clinical trial failures and regulatory setbacks.
- Competition from other immuno-oncology therapies.
- Patent expiration and generic competition.
- Economic downturn and reduced healthcare spending.
Competitive Advantages
- Proprietary TLR9 agonist technology.
- Patent protection for Tilsotolimod and other drug candidates.
- Expertise in immuno-oncology and rare disease drug development.
- Collaboration with Bristol-Meyers Squibb provides validation and resources.
About IDRA
Idera Pharmaceuticals, Inc., founded in 1989 and headquartered in Exton, Pennsylvania, is a biopharmaceutical company dedicated to the discovery, development, and potential commercialization of novel drugs for rare disease indications. The company's primary focus is on immuno-oncology, leveraging its expertise in Toll-like receptor (TLR) biology to develop targeted therapies. Their lead product candidate, Tilsotolimod (IMO-2125), is a synthetic phosphorothioate oligonucleotide designed to act as a direct agonist of TLR9. TLR9 is a receptor that plays a crucial role in activating the immune system. By stimulating TLR9, Tilsotolimod aims to enhance the body's natural defenses against cancer cells. Idera is exploring Tilsotolimod's potential in treating various solid tumors, including squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb, highlighting the potential of its technology and the interest from larger pharmaceutical companies. Idera's strategy involves identifying and developing therapies for niche indications with unmet medical needs, offering the potential for significant impact on patient outcomes.
What They Do
- Discovers and develops drugs for rare disease indications.
- Focuses on immuno-oncology, leveraging TLR biology.
- Offers Tilsotolimod (IMO-2125) as a lead product candidate.
- Tilsotolimod stimulates the immune system to fight cancer.
- Targets solid tumors, squamous cell carcinoma, and colorectal cancer.
- Collaborates with Bristol-Meyers Squibb.
Business Model
- Develops and patents novel drug candidates.
- Conducts preclinical and clinical trials to evaluate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- May commercialize products directly or through partnerships.
- Generates revenue through product sales, licensing agreements, and collaborations.
Industry Context
Idera Pharmaceuticals operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant clinical trial risks. The immuno-oncology segment, where Idera focuses, is experiencing rapid growth due to the success of checkpoint inhibitors and other immunotherapies. Companies like ALLK, ANGN, ANPC, FRLN, and GMTX represent Idera's peers, each pursuing different therapeutic approaches and target markets. The industry is driven by innovation, with companies constantly seeking novel targets and mechanisms of action to improve patient outcomes. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and effective commercialization strategies.
Key Customers
- Patients with rare diseases, particularly cancer.
- Oncologists and other healthcare professionals.
- Hospitals and cancer centers.
- Pharmaceutical companies through collaborations and licensing agreements.
IDRA Financials
IDRA Price Today & Live Chart
Idera Pharmaceuticals, Inc. (IDRA) stock price: Price data unavailable
IDRA Latest News
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Dec 28, 2022
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Dec 22, 2022
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Dec 15, 2022
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · May 11, 2022
IDRA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IDRA.
Price Targets
Wall Street price target analysis for IDRA.
IDRA MoonshotScore
What does this score mean?
The MoonshotScore rates IDRA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Vincent J. Milano
Chief Executive Officer
Vincent J. Milano is the Chief Executive Officer of Idera Pharmaceuticals, Inc. He has extensive experience in the pharmaceutical and biotechnology industries, with a background in finance and operations. Prior to joining Idera, he held leadership positions at various companies, including ViroPharma Incorporated and Centocor, Inc. His experience spans across multiple therapeutic areas and stages of drug development.
Track Record: Under Vincent Milano's leadership, Idera Pharmaceuticals has focused on advancing Tilsotolimod through clinical development and securing a collaboration agreement with Bristol-Meyers Squibb. He has overseen the company's strategic shift towards immuno-oncology and rare diseases. His tenure has been marked by efforts to secure funding and navigate the challenges of drug development.
Common Questions About IDRA (Healthcare)
What does Idera Pharmaceuticals, Inc. do?
Idera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for rare disease indications, particularly in immuno-oncology. Their lead product candidate, Tilsotolimod, is designed to stimulate the immune system to fight cancer by targeting TLR9. The company collaborates with larger pharmaceutical firms like Bristol-Meyers Squibb to advance its pipeline and explore new therapeutic opportunities. Idera's strategy centers on addressing unmet medical needs in niche markets, offering the potential for significant impact on patient outcomes.
What do analysts say about IDRA stock?
AI analysis is currently pending for IDRA. Generally, biotechnology companies like Idera are evaluated based on the potential of their drug pipeline, clinical trial results, and regulatory milestones. Key valuation metrics include the potential market size for their lead product candidates, the probability of success in clinical development, and the terms of any partnerships or licensing agreements. Investors should monitor clinical trial data, regulatory updates, and financial performance to assess the company's prospects.
What are the main risks for IDRA?
Idera Pharmaceuticals faces several key risks inherent to the biotechnology industry. Clinical trial failures or negative data readouts for Tilsotolimod represent a significant risk, as the company is heavily reliant on its lead product candidate. Regulatory delays or rejection by agencies like the FDA could also impede progress. Competition from other immuno-oncology therapies and the potential for patent expiration pose ongoing threats. Additionally, the company's dependence on future funding and capital raising creates financial risks, particularly given its current lack of profitability.
What are the key factors to evaluate for IDRA?
Idera Pharmaceuticals, Inc. (IDRA) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary TLR9 agonist technology with potential in immuno-oncology. Primary risk to monitor: Clinical trial failures or negative data readouts for Tilsotolimod. This is not financial advice.
How frequently does IDRA data refresh on this page?
IDRA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IDRA's recent stock price performance?
Recent price movement in Idera Pharmaceuticals, Inc. (IDRA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary TLR9 agonist technology with potential in immuno-oncology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IDRA overvalued or undervalued right now?
Determining whether Idera Pharmaceuticals, Inc. (IDRA) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IDRA?
Before investing in Idera Pharmaceuticals, Inc. (IDRA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.